All News

💊 Difficult-to-treat #SpA & #PsA 🤔 What are the challenges in assessing persistently active disease? 🗣️ Vinod Chandran takes us through the pearls and pitfalls in assessing D2T disease 🌎 Great to see #comorbidities highlighted @RheumNow #EULAR2024 https://t.co/x4jUTOC3li

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
Dr. G Schett reported using CAR-T cell Rx in patients w/ 1. pedi-SLE 2. CNS lupus 3. refractory cases with success. Post- Rx vaccine response is fine, infection risk is less since pts no longer need steroids. He is still following the pts for relapse and AEs @RheumNow #EULAR24

TheDaoIndex KDAO2011 ( View Tweet)

Consider the source and type of pain when managing axSpA including nociplastic pain. Difficult to treat axSpA #EULAR2024 Rudwaleit M @RheumNow https://t.co/4rszIyw5V6

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
CAR-T effective B cell depletion preserving plasma cell function @rheumnow #EULAR2024 https://t.co/mYmwC2cV6e

Links:

Peter Nash drpnash ( View Tweet)
« CAR T cells can change the therapeutic scenario: a short treatment for a prolonged efficacy » says G. Schett Are we finally looking at the « visionary scenario »? @RheumNow #EULAR2024 https://t.co/tzfDormeIl

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
@Janetbirdope @RheumNow #EULAR2024 JAK-i Debate @drdavidliew (NOT in support of regulation) - is the signal real? Query about replicability & data came from N. America. Not reflected on real-world data of enriched cohorts - is the warning justified? - are there unintended consequences? @RheumNow https://t.co/TXUf90fqwN

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Asking the quintessential Australian question at #EULAR24 by @drdavidliew - does the ORAL surveillance study for JAKi *truly* pass the pub test? @eular_org @Janetbirdope @RheumNow What does #MedTwitter think? https://t.co/bqwPU8XX5S

Links:

Benjamin Sutu benjaminsutu ( View Tweet)
Pt with LN, endocarditis, pericarditis, arthritis, rash failed CTX, MMF, BEL, and SOC. She is 1000 days post CAR-T cell. Off immunomodulating drugs. #SLE in remission clinically and serologically. - Dr G Schett #EULAR24 @RheumNow https://t.co/3vdMtO6VWI

Links:

TheDaoIndex KDAO2011 ( View Tweet)
#EULAR2024 JAK-i Debate. @Janetbirdope [Pro Regulatory Safety Measures] - to do no harm esp since there are other alternatives - supported by RCT - although JAK-i have different structures, data from individual RCT + LTE showed similar rates of malignancy & MACE @RheumNow https://t.co/jQKQmHE9Fg

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Areas to consider in difficult to manage PsA and research agenda #EULAR2024 Chandran V @RheumNow https://t.co/sp4tkAivLa

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Significant proportion of patients in PsA do not achieve remission across the domains. This can be due to disease heterogeneity, domain differences, comorbidities. There is a need to study the use of combination ts and bDMARDs. Difficult to Manage PsA session #EULAR2024 Ribeiro,… https://t.co/Wt3jgtIR9N https://t.co/VzCApikqek

Links:

Dr. Antoni Chan synovialjoints ( View Tweet)
Join us later for a some very exciting pieces of translational science across a AIRDs. All these abstracts sharing one thing in common: tissue, tissue, tissue! 16:30-18:00 Room A8.2 @RheumNow #EULAR2024 https://t.co/HrHP5tmHDD

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
Grappa - distinguish D2T from complex to manage - objective signs of inflammation imaging - US or MRI not lab markers @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

#EULAR2024 Eular Debate Showdown between @Janetbirdope vs @drdavidliew Topic: can observational study debunk RCT? This stemmed from Oral Surveillance = an increased risk of malignany & MACE with tofacitinib compared with TNF-i. Regulatories extrapolated to all JAK-i @RheumNow https://t.co/hg6xJZDHiA

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The great debate on JAKi risk and special warnings And who better than @RheumNow to keep score between @Janetbirdope & @drdavidliew Get the popcorn ready 🍿 #EULAR2024 https://t.co/z50Ob8q0i0

Links:

Aurelie Najm AurelieRheumo ( View Tweet)
almost half PsA patients have 3 pr more co-morbidities and 67% of those surveyed do not think rheumos should not manage them - when did we stop being physicians ? @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

« difficult to treat PsA » how mich combination obesity, non-inflammatory MSK pain, fibromyalgia and depression making assessment tricky and risk of rattling through therapies fast! @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

Dr. D Aletaha defines The #EULARManifesto, "It is about patient centeredness-- improving quality of care, advocating for patients, timely access to specialists, pushing R&D innovation, integrating technology to make sure every patient gets the care they need." @rheumnow #EULAR24

TheDaoIndex KDAO2011 ( View Tweet)

🌎 Global disparities in steroid prescribing in #SLE 💊 HCQ assoc with decreased steroid use 📈 Other contributing factors may be prevalence, severity & phenotype of disease, plus access to DMARDs & biologics 📍SLE poster tour 15:30 TODAY #EULAR2024 Abs #POS0013 @RheumNow https://t.co/7pL8kpeqOs

Links:

Mrinalini Dey DrMiniDey ( View Tweet)
LBA0001 (2024) EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH GIANT CELL ARTERITIS (SELECT-GCA): A DOUBLE-BLIND, RANDOMIZED CONTROLLED PHASE 3 TRIAL - looking good, nice results @rheumnow #EULAR2024

Peter Nash drpnash ( View Tweet)

×